Could a common heart drug boost ovarian cancer treatment?

NCT ID NCT07125391

Recruiting now Disease control Sponsor: Bai-Rong Xia Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding propranolol, a widely used beta-blocker, to standard chemotherapy before surgery can improve outcomes for women with advanced high-grade serous ovarian cancer. Participants receive propranolol pills alongside paclitaxel and carboplatin, followed by surgery to remove tumors. The study aims to see if this combination leads to better tumor shrinkage and more complete surgical removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: propranolol hydrochloride
What this could lead to: If successful, adding propranolol to standard chemotherapy could improve surgical outcomes and extend survival for women with advanced ovarian cancer.
What could go wrong: This is a phase 2 trial with 136 participants, so results are preliminary. Propranolol may cause side effects like low blood pressure or fatigue, and the benefit seen in earlier studies may not hold up.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE SEROUS OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Anhui Cancer Hospitail
RECRUITING

Hefei, Anhui, 230001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.